Chemotargets will contribute to the development of the repurposing platform for the REMEDi4ALL project, using its technology platforms: ProSurfScan, for AI-based drug design; CLARITY, for efficacy and safety prediction of…
Read More
A formal collaboration to advance a common internal pipeline of drug development projects Barcelona, 16 March 2022 – Today we announce the start of the formal collaboration between Acellera…
CloudScientific as the local distributor in China of Chemotargets’ CLARITY and CLARITY PV technology platforms Shanghai, China and Barcelona, Spain – January 17th, 2022. Chemotargets is proud to appoint CloudScientific as the local…
Drug discovery biotech firm Chemotargets and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical...
Read More
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven…
This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between both institutions. Chemotargets has entered into a strategic alliance with the IMIM Hospital del…
The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting the FDA’s mission of protecting public health. Barcelona / Washington D.C., USA: The Food and Drug Administration’s Center…
Barcelona, May 2017 – Prous Institute for Biomedical Research announced today that it has made a strategic investment in Chemotargets SL. Founded by Dr. Jordi Mestres as a spin-off of...
Read More
